McKesson (MCK)
(Delayed Data from NYSE)
$550.72 USD
+3.25 (0.59%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $551.01 +0.29 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$550.72 USD
+3.25 (0.59%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $551.01 +0.29 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
McKesson (MCK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed at $354.48 in the latest trading session, marking a +1.45% move from the prior day.
Is Henry Schein (HSIC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
McKesson (MCK) Stock Moves -1.63%: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $341.82, marking a -1.63% move from the previous day.
McKesson (MCK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $339.92, marking a +1.36% move from the previous day.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
McKesson (MCK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed the most recent trading day at $336.20, moving +0.07% from the previous trading session.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment
by Zacks Equity Research
Nevro's (NVRO) Senza HFX iQ SCS system is expected to treat individual patients per their particular treatment requirements.
Here's Why You Should Retain Catalent (CTLT) Stock for Now
by Zacks Equity Research
Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.
Cardinal Health's (CAH) New Tie-Up to Boost Patient Outcomes
by Zacks Equity Research
Cardinal Health's (CAH) latest partnership is expected to improve patients' healthcare journey by offering a more integrated experience that connects all sites of care.
Three Reasons to Add BD (BDX) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.
All You Need to Know About McKesson (MCK) Rating Upgrade to Buy
by Zacks Equity Research
McKesson (MCK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Walgreens Boots (WBA) Benefits From New Launches Amid FX Woes
by Zacks Equity Research
Walgreens Boots' (WBA) comparable pharmacy sales decline, reflecting lower demand for COVID-19 services.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cooper Companies (COO) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cooper Companies' (COO) first-quarter fiscal 2023 revenues reflect a solid segmental performance despite a year-over-year decline in earnings.
NextGen (NXGN) Behavioral Health Suite Adopted by Compass Health
by Zacks Equity Research
NextGen's (NXGN) Behavioral Health Suite is expected to aid Compass Health in improving its workflow.
Zacks.com featured highlights Hershey's, ParkerHannifin, Interpublic Group, Microchip Technology and McKesson
by Zacks Equity Research
Hershey's, ParkerHannifin, Interpublic Group, Microchip Technology and McKesson have been highlighted in this Screen of The Week article.
Veeva Systems (VEEV) Q4 Earnings Beat, Margins Decline
by Zacks Equity Research
Veeva Systems' (VEEV) Q4 results reflect impressive performances by both segments.
National Vision (EYE) Q4 Revenues Miss Mark, Margins Down
by Zacks Equity Research
National Vision (EYE) is facing a challenging macroeconomic environment, which negatively impacted its performance in the fourth quarter of 2022.
Patterson Companies (PDCO) Q3 Earnings Beat, Sales Hurt by FX
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter 2023 results are negatively impacted by unfavorable currency movements.
5 Smart Beta Dividend Stocks to Buy Now for Steady Gains
by Sweta Killa
Hershey (HSY), ParkerHannifin (PH), The Interpublic Group (IPG), Microchip Technology (MCHP), and McKesson (MCK) could be solid choices for your portfolio amid rising yields.
Myriad Genetics (MYGN) Q4 Earnings Top, Gross Margin Falls
by Zacks Equity Research
Myriad Genetics (MYGN) hereditary cancer testing volume registered strong growth in the fourth quarter. GeneSight comes up with yet another strong performance.
After Plunging -7.62% in 4 Weeks, Here's Why the Trend Might Reverse for McKesson (MCK)
by Zacks Equity Research
The heavy selling pressure might have exhausted for McKesson (MCK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Masimo (MASI) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q4 sales.